Notable alterations included those occurring in genes involved in DNA repair genes BRCA1/2 or ATM (20 mutations in 19 tumors (21.6%) combined), which sensitize the tumor for poly (ADP‐ribose) polymerase (PARP) inhibitors.18, 19 Of these, somatic BRCA1 mutations were identified in 4 (4.5%) tumors, including 2 truncating mutations (E699* and C1382Sfs*11), 1 homozygous deletion, and 1 single nucleotide variant (SNV) that affected a splice donor site (c.4096 + 1G > T). This evidence concerns the gene BRCA1 and neoplasm.